Table 3.
CSS of women with breast cancer according to treatment initiation before and after 45 Days.
| Variable | Calculated survival at 5 years from initial treatment (%) |
p-value* | |
|---|---|---|---|
| <45 days | >45 days | ||
| 590 (%)a | 130 (%)a | ||
| Age at diagnosis (years) | |||
| <45 | 83.9 | 81.6 | 0.434 |
| >45 | 83.5 | 84.5 | |
| Body Mass Index | |||
| Normal | 84.6 | 81.3 | |
| Overweight | 82.1 | 79.9 | 0.058 |
| Obesity | 84.5 | 84.8 | |
| Hormonal status | |||
| Premenopausal | 82.3 | 78.9 | 0.732 |
| Postmenopausal | 84.4 | 84.3 | |
| Clinical stage | |||
| I | 95.2 | 90.6 | |
| IIA | 92.0 | 87.8 | |
| IIB | 89.5 | 89.2 | <0.001 |
| IIIA | 78.1 | 63.6 | |
| IIIB | 62.9 | 57.4 | |
| Histology | |||
| Infiltrating ductal | 83.6 | 83.5 | 0.303 |
| Infiltrating lobular | 86.4 | 75.0 | |
| Tumor size | |||
| <2 cm | 92.7 | 84.3 | |
| 2–5 cm | 88.2 | 86.4 | <0.001 |
| >5 cm | 71.6 | 72.0 | |
| Nuclear grade | |||
| Well differentiated | 92.7 | 90.6 | |
| Moderately differentiated | 87.6 | 80.7 | 0.162 |
| Poorly differentiated | 77.4 | 78.0 | |
| Lymphovascular invasion | |||
| Absent | 84.2 | 84.9 | 0.361 |
| Present | 81.3 | 81.4 | |
| Estrogen receptor expression | |||
| Negative | 77.1 | 74.8 | 0.219 |
| Positive | 87.6 | 87.2 | |
| Progesterone receptor expression | |||
| Negative | 79.1 | 80.1 | <0.001 |
| Positive | 87.4 | 86.7 | |
| Molecular classification | |||
| Luminal A | 88.5 | 88.0 | |
| Luminal B | 86.9 | 53.3 | <0.001 |
| Her2 Neu | 84.7 | 62.5 | |
| Triple negative | 67.7 | 66.0 | |
| Lymph node invasion | .001 | ||
| No | 94.5 | 93.7 | <0.001 |
| Yes | 79.0 | 75.9 | |
a
Kaplan Meier Method.
*
Log-Rank Test.